Pyxis Oncology Inc (PYXS) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Pyxis Oncology Inc (PYXS) has a cash flow conversion efficiency ratio of -0.193x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-13.28 Million) by net assets ($68.78 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Check asset allocation strategy of Pyxis Oncology Inc to assess the company's strategic physical and investment asset allocation.
Pyxis Oncology Inc - Cash Flow Conversion Efficiency Trend (2019–2024)
This chart illustrates how Pyxis Oncology Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. See what is Pyxis Oncology Inc's book value for net asset value and shareholders' equity analysis.
Pyxis Oncology Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Pyxis Oncology Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Jeil Pharm
KO:002620
|
0.004x |
|
Silvercrest Asset Management Group Inc
NASDAQ:SAMG
|
0.175x |
|
Baoye Group Company Limited
F:BKG
|
0.006x |
|
Dwarikesh Sugar Industries Limited
NSE:DWARKESH
|
0.740x |
|
Valuence Merger Corp I
NASDAQ:VMCA
|
-0.014x |
|
Alcadon Group AB
ST:ALCA
|
0.063x |
|
Aditya Birla Money Limited
NSE:BIRLAMONEY
|
0.060x |
|
IBI Lion SOCIMI S.A.
MC:YIBI
|
0.006x |
Annual Cash Flow Conversion Efficiency for Pyxis Oncology Inc (2019–2024)
The table below shows the annual cash flow conversion efficiency of Pyxis Oncology Inc from 2019 to 2024. For the full company profile with market capitalisation and key ratios, see Pyxis Oncology Inc (PYXS) market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $120.75 Million | $-57.67 Million | -0.478x | +15.09% |
| 2023-12-31 | $125.70 Million | $-70.71 Million | -0.563x | -1.26% |
| 2022-12-31 | $160.82 Million | $-89.33 Million | -0.555x | -310.90% |
| 2021-12-31 | $261.31 Million | $-35.33 Million | -0.135x | -120.97% |
| 2020-12-31 | $-15.64 Million | $-10.08 Million | 0.645x | -17.26% |
| 2019-12-31 | $-2.87 Million | $-2.24 Million | 0.779x | -- |
About Pyxis Oncology Inc
Pyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat solid tumors. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candida… Read more